{"pmid":32335068,"title":"Unexpected Blood Pressure Sensitivity to Angiotensin II in a COVID-19 Patient with ARDS and Septic Shock.","text":["Unexpected Blood Pressure Sensitivity to Angiotensin II in a COVID-19 Patient with ARDS and Septic Shock.","We report the case of an 88-year-old man with coronavirus disease 2019 (COVID-19) who presented with ARDS and septic shock. The patient had exquisite blood pressure sensitivity to low-dose angiotensin II (Ang-2), allowing for rapid liberation from high-dose vasopressors. We hypothesize that sensitivity to Ang-2 might be related to biologic effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our case is suggestive of a potential role for synthetic Ang-2 for patients with COVID-19 and septic shock. Further studies are needed to confirm our observed clinical efficacy.","Chest","Wang, Hanyin","Das, Subhraleena","Wieruszewski, Patrick M","Taji, Jamil","Bartlett, Brian","Azad, Nabila","Chowdhury, Arnab","Kolar, Gururaj","Jain, Nitesh","Subla, Mir R","Khan, Syed Anjum","32335068"],"abstract":["We report the case of an 88-year-old man with coronavirus disease 2019 (COVID-19) who presented with ARDS and septic shock. The patient had exquisite blood pressure sensitivity to low-dose angiotensin II (Ang-2), allowing for rapid liberation from high-dose vasopressors. We hypothesize that sensitivity to Ang-2 might be related to biologic effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our case is suggestive of a potential role for synthetic Ang-2 for patients with COVID-19 and septic shock. Further studies are needed to confirm our observed clinical efficacy."],"journal":"Chest","authors":["Wang, Hanyin","Das, Subhraleena","Wieruszewski, Patrick M","Taji, Jamil","Bartlett, Brian","Azad, Nabila","Chowdhury, Arnab","Kolar, Gururaj","Jain, Nitesh","Subla, Mir R","Khan, Syed Anjum"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335068","week":"202018|Apr 27 - May 03","doi":"10.1016/j.chest.2020.04.015","keywords":["angiotensin ii","covid-19","sars-cov-2","septic shock"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1665172301949173761,"score":8.518259,"similar":[{"pmid":32222713,"title":"A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease.","text":["A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease.","Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease with an alarming case fatality rate up to 5%. The risk factors for severe presentations are concentrated in patients with chronic kidney disease, particularly patients with end-stage renal disease (ESRD) who are dialysis dependent. We report the first US case of a 56-year-old nondiabetic male with ESRD secondary to IgA nephropathy undergoing thrice-weekly maintenance hemodialysis for 3 years, who developed COVID-19 infection. He has hypertension controlled with angiotensin receptor blocker losartan 100 mg/day and coronary artery disease status-post stent placement. During the first 5 days of his febrile disease, he presented to an urgent care, 3 emergency rooms, 1 cardiology clinic, and 2 dialysis centers in California and Utah. During this interval, he reported nausea, vomiting, diarrhea, and low-grade fevers but was not suspected of COVID-19 infection until he developed respiratory symptoms and was admitted to the hospital. Imaging studies upon admission were consistent with bilateral interstitial pneumonia. He was placed in droplet-eye precautions while awaiting COVID-19 test results. Within the first 24 h, he deteriorated quickly and developed acute respiratory distress syndrome (ARDS), requiring intubation and increasing respiratory support. Losartan was withheld due to hypotension and septic shock. COVID-19 was reported positive on hospital day 3. He remained in critical condition being treated with hydroxychloroquine and tocilizumab in addition to the standard medical management for septic shock and ARDS. Our case is unique in its atypical initial presentation and highlights the importance of early testing.","Am J Nephrol","Ferrey, Antoney J","Choi, Grace","Hanna, Ramy M","Chang, Yongen","Tantisattamo, Ekamol","Ivaturi, Kaushik","Park, Elisa","Nguyen, Lawrence","Wang, Brian","Tonthat, Sam","Rhee, Connie M","Reddy, Uttam","Lau, Wei Ling","Huang, Susan S","Gohil, Shruti","Amin, Alpesh N","Hsieh, Lanny","Cheng, Timmy T","Lee, Richard A","Kalantar-Zadeh, Kamyar","32222713"],"abstract":["Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease with an alarming case fatality rate up to 5%. The risk factors for severe presentations are concentrated in patients with chronic kidney disease, particularly patients with end-stage renal disease (ESRD) who are dialysis dependent. We report the first US case of a 56-year-old nondiabetic male with ESRD secondary to IgA nephropathy undergoing thrice-weekly maintenance hemodialysis for 3 years, who developed COVID-19 infection. He has hypertension controlled with angiotensin receptor blocker losartan 100 mg/day and coronary artery disease status-post stent placement. During the first 5 days of his febrile disease, he presented to an urgent care, 3 emergency rooms, 1 cardiology clinic, and 2 dialysis centers in California and Utah. During this interval, he reported nausea, vomiting, diarrhea, and low-grade fevers but was not suspected of COVID-19 infection until he developed respiratory symptoms and was admitted to the hospital. Imaging studies upon admission were consistent with bilateral interstitial pneumonia. He was placed in droplet-eye precautions while awaiting COVID-19 test results. Within the first 24 h, he deteriorated quickly and developed acute respiratory distress syndrome (ARDS), requiring intubation and increasing respiratory support. Losartan was withheld due to hypotension and septic shock. COVID-19 was reported positive on hospital day 3. He remained in critical condition being treated with hydroxychloroquine and tocilizumab in addition to the standard medical management for septic shock and ARDS. Our case is unique in its atypical initial presentation and highlights the importance of early testing."],"journal":"Am J Nephrol","authors":["Ferrey, Antoney J","Choi, Grace","Hanna, Ramy M","Chang, Yongen","Tantisattamo, Ekamol","Ivaturi, Kaushik","Park, Elisa","Nguyen, Lawrence","Wang, Brian","Tonthat, Sam","Rhee, Connie M","Reddy, Uttam","Lau, Wei Ling","Huang, Susan S","Gohil, Shruti","Amin, Alpesh N","Hsieh, Lanny","Cheng, Timmy T","Lee, Richard A","Kalantar-Zadeh, Kamyar"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222713","week":"202014|Mar 30 - Apr 05","doi":"10.1159/000507417","keywords":["Acute respiratory distress syndrome","End-stage renal disease","Novel coronavirus disease 19","Rennin-angiotensin-aldosterone system blockade","Viral sepsis"],"source":"PubMed","locations":["California","Losartan","US","Utah"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Case Report"],"weight":1,"e_drugs":["tocilizumab","Losartan","Hydroxychloroquine"],"_version_":1663352135214956544,"score":244.97002},{"pmid":32286213,"title":"[Fatal outcome of coronavirus disease 2019 in a previously healthy 50-year-old man].","text":["[Fatal outcome of coronavirus disease 2019 in a previously healthy 50-year-old man].","In this case report, a 50-year-old man who had no medical history, presented with multiple cardiac arrests following a week with progressing symptoms of pneumonia. After achieving return of spontaneous circulation he presented with respiratory failure with severe hypoxia, septic shock, and multiple organ failure. A chest X-ray showed signs of acute respiratory distress syndrome. Despite aggressive intensive care management, the patient died 7.5 hours after admission. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was later confirmed, and the presumed cause of death was SARS-CoV-2 pneumonia. In conclusion: coronavirus disease 2019 (COVID-19) can lead to a fatal outcome in younger healthy residents, who are not treated timely in case of severe symptoms like dyspnoea.","Ugeskr Laeger","Wissenberg, Mads","Andersen, Lars Peter Kloster","Pallisgaard, Jannik Langtved","Lawson-Smith, Pia","32286213"],"abstract":["In this case report, a 50-year-old man who had no medical history, presented with multiple cardiac arrests following a week with progressing symptoms of pneumonia. After achieving return of spontaneous circulation he presented with respiratory failure with severe hypoxia, septic shock, and multiple organ failure. A chest X-ray showed signs of acute respiratory distress syndrome. Despite aggressive intensive care management, the patient died 7.5 hours after admission. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was later confirmed, and the presumed cause of death was SARS-CoV-2 pneumonia. In conclusion: coronavirus disease 2019 (COVID-19) can lead to a fatal outcome in younger healthy residents, who are not treated timely in case of severe symptoms like dyspnoea."],"journal":"Ugeskr Laeger","authors":["Wissenberg, Mads","Andersen, Lars Peter Kloster","Pallisgaard, Jannik Langtved","Lawson-Smith, Pia"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32286213","week":"202016|Apr 13 - Apr 19","source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664636391631355904,"score":230.528},{"pmid":32275347,"title":"Myocardial localization of coronavirus in COVID-19 cardiogenic shock.","text":["Myocardial localization of coronavirus in COVID-19 cardiogenic shock.","We describe the first case of acute cardiac injury directly linked to myocardial localization of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in a 69-year-old patient with flu-like symptoms rapidly degenerating into respiratory distress, hypotension, and cardiogenic shock. The patient was successfully treated with venous-arterial extracorporeal membrane oxygenation (ECMO) and mechanical ventilation. Cardiac function fully recovered in 5 days and ECMO was removed. Endomyocardial biopsy demonstrated low-grade myocardial inflammation and viral particles in the myocardium suggesting either a viraemic phase or, alternatively, infected macrophage migration from the lung.","Eur J Heart Fail","Tavazzi, Guido","Pellegrini, Carlo","Maurelli, Marco","Belliato, Mirko","Sciutti, Fabio","Bottazzi, Andrea","Sepe, Paola Alessandra","Resasco, Tullia","Camporotondo, Rita","Bruno, Raffaele","Baldanti, Fausto","Paolucci, Stefania","Pelenghi, Stefano","Iotti, Giorgio Antonio","Mojoli, Francesco","Arbustini, Eloisa","32275347"],"abstract":["We describe the first case of acute cardiac injury directly linked to myocardial localization of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in a 69-year-old patient with flu-like symptoms rapidly degenerating into respiratory distress, hypotension, and cardiogenic shock. The patient was successfully treated with venous-arterial extracorporeal membrane oxygenation (ECMO) and mechanical ventilation. Cardiac function fully recovered in 5 days and ECMO was removed. Endomyocardial biopsy demonstrated low-grade myocardial inflammation and viral particles in the myocardium suggesting either a viraemic phase or, alternatively, infected macrophage migration from the lung."],"journal":"Eur J Heart Fail","authors":["Tavazzi, Guido","Pellegrini, Carlo","Maurelli, Marco","Belliato, Mirko","Sciutti, Fabio","Bottazzi, Andrea","Sepe, Paola Alessandra","Resasco, Tullia","Camporotondo, Rita","Bruno, Raffaele","Baldanti, Fausto","Paolucci, Stefania","Pelenghi, Stefano","Iotti, Giorgio Antonio","Mojoli, Francesco","Arbustini, Eloisa"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275347","week":"202015|Apr 06 - Apr 12","doi":"10.1002/ejhf.1828","keywords":["cardiac injury","cardiogenic shock","coronavirus","extracorporeal membrane oxygenation","myocardial inflammation","sars-cov-2"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664637190233128960,"score":203.77946},{"pmid":32304394,"title":"First successful treatment of COVID-19 induced refractory cardiogenic plus vasoplegic shock by combination of pVAD and ECMO - a case report.","text":["First successful treatment of COVID-19 induced refractory cardiogenic plus vasoplegic shock by combination of pVAD and ECMO - a case report.","The novel coronavirus SARS-CoV-2 is infecting hundreds of thousands of humans around the globe. The coronavirus disease COVID-19 is known to generate mild as well as critical courses. Complications on the intensive care units include acute respiratory distress syndrome, acute cardiac- and kidney injury as well as shock.Here, we present the first case report of a successful treatment of a COVID-19 patient presenting with ARDS plus refractory combined cardiogenic and vasoplegic shock, which could be successfully stabilized after implantation of a percutaneous ventricular assist device (pVAD) plus an extracorporeal membrane oxygenation (ECMO).While such intense treatment might not be feasible in case of a health care disaster as described for the hot spots of the COVID-19 pandemic, it might encourage treatment of younger patients on intensive care units not overcrowded by critically ill patients.","ASAIO J","Bemtgen, Xavier","Kruger, Kirsten","Supady, Alexander","Durschmied, Daniel","Schibilsky, David","Bamberg, Fabian","Bode, Christoph","Wengenmayer, Tobias","Staudacher, Dawid L","32304394"],"abstract":["The novel coronavirus SARS-CoV-2 is infecting hundreds of thousands of humans around the globe. The coronavirus disease COVID-19 is known to generate mild as well as critical courses. Complications on the intensive care units include acute respiratory distress syndrome, acute cardiac- and kidney injury as well as shock.Here, we present the first case report of a successful treatment of a COVID-19 patient presenting with ARDS plus refractory combined cardiogenic and vasoplegic shock, which could be successfully stabilized after implantation of a percutaneous ventricular assist device (pVAD) plus an extracorporeal membrane oxygenation (ECMO).While such intense treatment might not be feasible in case of a health care disaster as described for the hot spots of the COVID-19 pandemic, it might encourage treatment of younger patients on intensive care units not overcrowded by critically ill patients."],"journal":"ASAIO J","authors":["Bemtgen, Xavier","Kruger, Kirsten","Supady, Alexander","Durschmied, Daniel","Schibilsky, David","Bamberg, Fabian","Bode, Christoph","Wengenmayer, Tobias","Staudacher, Dawid L"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304394","week":"202016|Apr 13 - Apr 19","doi":"10.1097/MAT.0000000000001178","source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664632934571704320,"score":168.71928},{"pmid":32241695,"title":"SARS-CoV-2 outbreak: How can pharmacists help?","text":["SARS-CoV-2 outbreak: How can pharmacists help?","Coronaviruses (CoVs) are a large family of viruses that cause disorders ranging from a mild cold to severe disease. Some of the CoVs are zoonotic, meaning they can be transmitted from animals to humans. In December 2019, the world awoke to a new zoonotic strain of CoV that was named SARS-CoV-2 (standing for severe acute respiratory syndrome coronavirus 2), which has been classified as a high-consequence infectious disease. In addition, serious complications related to COVID-19 have been reported in some patients. These include acute respiratory distress syndrome, acute renal failure, septic shock and ventilator-associated pneumonia. The pharmacist, as a healthcare practitioner, can play an important role in hindering the spread of COVID-19, and can be an active participant in national and community efforts to fight and contain this outbreak.","Res Social Adm Pharm","Al-Quteimat, Osama M MSc, BCOP","Amer, Amer Mustafa R.Ph, MSc","32241695"],"abstract":["Coronaviruses (CoVs) are a large family of viruses that cause disorders ranging from a mild cold to severe disease. Some of the CoVs are zoonotic, meaning they can be transmitted from animals to humans. In December 2019, the world awoke to a new zoonotic strain of CoV that was named SARS-CoV-2 (standing for severe acute respiratory syndrome coronavirus 2), which has been classified as a high-consequence infectious disease. In addition, serious complications related to COVID-19 have been reported in some patients. These include acute respiratory distress syndrome, acute renal failure, septic shock and ventilator-associated pneumonia. The pharmacist, as a healthcare practitioner, can play an important role in hindering the spread of COVID-19, and can be an active participant in national and community efforts to fight and contain this outbreak."],"journal":"Res Social Adm Pharm","authors":["Al-Quteimat, Osama M MSc, BCOP","Amer, Amer Mustafa R.Ph, MSc"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32241695","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.sapharm.2020.03.018","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664638249333686272,"score":164.2613}]}